(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 October 2011 (06.10.2011)

PCT

(10) International Publication Number
WO 2011/123456 A1

(51) International Patent Classification:
A61K 38/48 (2006.01) *A61P 21/02* (2006.01)

(21) International Application Number:
PCT/US2011/030370

(22) International Filing Date:
29 March 2011 (29.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/319,230 30 March 2010 (30.03.2010) US
61/320,667 2 April 2010 (02.04.2010) US

(71) Applicant *(for all designated States except US)*: **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, T2-7H, Irvine, California 92612 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **TURKEL, Catherine C.** [US/US]; 19 Suprema Drive, Newport Coast, California 92657 (US). **AURORA, Sheena K.** [US/US]; 5609 SW Bradford Street, Seattle, Washington 98116-3577 (US). **DODICK, David W.** [US/US]; 11392 Carribean Lane, Scottsdale, Arizona 85259 (US). **BRIN, Mitchell F.** [US/US]; 30 San Antonio, Newport Beach, California 92660 (US).

(74) Agents: **ABEL, Kenton B.** et al.; Allergan, Inc., 2525 Dupont Drive, Irvine, California 92612 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

(54) **Title**: BOTULINUM TOXIN DOSAGE REGIMEN FOR CHRONIC MIGRAINE PROPHYLAXIS




FIG. 17

(57) **Abstract**: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering from chronic migraine. The injection schedule requires a minimum dose of 155 U using a fixed-site, fixed- dose injection regimen into 31-39 sites across 7 head/nech muscles, namely the frontalis, corrugator, procerus, occipitalis, temporalis, trapezius and cervical paraspinal muscles.

WO 2011/123456 A1